---
title: "Annex 1 Compliance Signals from FDA Warning Letters"
description: "What do 230 FDA warning letters reveal about recurring sterile manufacturing deficiencies? This white paper analyses inspection findings from 2023–2025 and maps them to EU GMP Annex 1 expectations, revealing where manufacturers most frequently fall short of sustainable compliance."
url: https://qbdgroup.com/zh-cn/downloads/annex-1-compliance-signals-fda-warning-letters
type: "White paper"
language: zh-cn
published: 2026-03-13
author: "Jo Doucet & Stan Van Kerkhoven"
category: "Quality Assurance"
publisher: "QbD Group"
citation: "QbD Group, \"Annex 1 Compliance Signals from FDA Warning Letters\", https://qbdgroup.com/zh-cn/downloads/annex-1-compliance-signals-fda-warning-letters"
---
# Annex 1 Compliance Signals from FDA Warning Letters
> What do 230 FDA warning letters reveal about recurring sterile manufacturing deficiencies? This white paper analyses inspection findings from 2023–2025 and maps them to EU GMP Annex 1 expectations, revealing where manufacturers most frequently fall short of sustainable compliance.

Since the implementation of the revised EU GMP Annex 1, regulatory scrutiny of sterile manufacturing has intensified worldwide.

This white paper analyses 230 FDA warning letters and identifies recurring deficiencies that directly relate to Annex 1 contamination control principles.

Rather than isolated technical issues, many inspection findings reveal systemic weaknesses in contamination control strategies and Pharmaceutical Quality System governance.

## What you'll learn

In this white paper, you'll discover:

- The most common sterile manufacturing deficiencies observed in FDA warning letters
- How these observations relate to EU GMP Annex 1 requirements
- The eight recurring compliance domains affecting sterility assurance
- Practical insights to strengthen contamination control and inspection readiness

## Download the white paper

Discover where sterile manufacturing systems most frequently fail to meet Annex 1 expectations, and how to address these gaps.

Complete the form to access the full report.

<!-- cta_url:/en/industries/pharma-biotech/manufacturing-quality-compliance -->
<!-- cta_label:Strengthen your Annex 1 compliance strategy -->
---
Source: https://qbdgroup.com/zh-cn/downloads/annex-1-compliance-signals-fda-warning-letters — © QbD Group. Quote freely with attribution and a link back.